Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series

Authors

Institutions

Publication Details

Journal
Hematology
Published
2025-06-17
DOI
https://doi.org/10.1080/16078454.2025.2519896
Primary Topic
Peripheral Neuropathies and Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series

Kazumoto Shibuya, Satoshi Kuwabara, Emiko Sakaida, Shokichi Tsukamoto et al.
1 links
Hematology
Peripheral Neuropathies and Disorders
article

Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series

Kazumoto Shibuya, Satoshi Kuwabara, Emiko Sakaida, Shokichi Tsukamoto, Naoya Mimura, Sonoko Misawa, Tomoki Suichi, Marie Morooka, Moeko Ogushi, Nagisa Oshima‐Hasegawa, Yusuke Takeda
article en

Abstract

No abstract available for this paper.
HematologyVol. 30(1)
Chiba University (JP), Chiba University Hospital (JP)
Ministry of Health, Labour and Welfare
Openalex Percentile: Top 78%
Peripheral Neuropathies and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.